Molecular magnetic resonance imaging in cancer

Mohammad Haris¹, Santosh K. Yadav¹, Arshi Rizwan², Anup Singh³, Ena Wang¹, Hari Hariharan⁴, Ravinder Reddy⁴ and Francesco M. Marincola¹

Abstract
The ability to identify key biomolecules and molecular changes associated with cancer malignancy and the capacity to monitor the therapeutic outcome against these targets is critically important for cancer treatment. Recent developments in molecular imaging based on magnetic resonance (MR) techniques have provided researchers and clinicians with new tools to improve most facets of cancer care. Molecular imaging is broadly described as imaging techniques used to detect molecular signature at the cellular and gene expression levels. This article reviews both established and emerging molecular MR techniques in oncology and discusses the potential of these techniques in improving the clinical cancer care. It also discusses how molecular MR, in conjunction with other structural and functional MR imaging techniques, paves the way for developing tailored treatment strategies to enhance cancer care.

Keywords: Cancer, Magnetic resonance imaging, Magnetic resonance spectroscopy, Hyperpolarization, Chemical exchange saturation transfer (CEST) imaging, Reporter genes, Cancer immunotherapy

Background
Advancement in understanding of molecular and cellular processes in cancer led to the development of various imaging based techniques, which can monitor these processes non-invasively in vivo and provide opportunity to better describe cancer biology, and to assess therapeutic targets. Imaging techniques which target these molecular and cellular physiologies are grouped under a broad term “molecular imaging”. Molecular imaging provides a new approach to image and characterize the key biomolecules and molecular changes associated with the cancer malignancy [1]. Molecular Imaging offers non-invasive and repetitive detection of cancer cellular-biochemistry and physiology in vivo, which may help to predict the tumor response against a specific treatment and may provide more definite criteria for patient selection to identify those that would respond to treatment.

Various imaging modalities including single photon emission computed tomography (SPECT), positron emission tomography (PET), optical imaging, magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) have been widely used to monitor structural, functional, and molecular changes in cancer tissues both clinically and pre-clinically [2–12]. PET and SPECT use radiotracers to image and measure the biological activity at targeted site, and are generally considered as molecular imaging modalities. However, despite exquisite sensitivity they are beset by poor resolution and the application of nuclear radiation may preclude their use for repetitive measurements in a short time period. Optical imaging has been used to image specific molecular features of cancer by employing molecular targeted contrast agents [7, 13]. Studies have suggested that optical based method can provide early information of treatment efficacy [14, 15]. However, requirement of the optical probe insertion in tissue limits its repetitive use, and also it is not suitable for studying parts of tissue that are distant from the probe.

Due to its non-invasive characteristics and high spatial resolution, MRI is one of the most powerful imaging tools available in diagnostic imaging, and has been readily used in preclinical research studies too. Recent development of new MR methods, which focus on imaging of molecular signatures, and development of novel molecular contrast...
agents have expanded the strength of MRI in characterizing tissue physiological and molecular changes. In this review article, we outline different molecular MR imaging techniques describing cellular and molecular changes in cancer, and their roles in cancer prognosis, staging and monitoring therapeutic efficacy.

Review

Imaging of cancer metabolism

Altered cellular metabolism is key for cancer growth and malignancy [16, 17]. Many of the biochemical pathways particularly, glycolysis, pentose phosphate pathway (PPP), and TCA cycle are subjected to alternative regulation in cancer cells [18–23]. Monitoring and understanding the cancer metabolism in vivo drastically improves diagnosis and treatment planning of cancer. It was Otto Warburg who demonstrated high glucose consumption and lactate production in cancer compared to healthy tissues and conceptualized that tumor metabolism differs from that of normal tissue [24, 25]. This pivotal observation created a field of tumor metabolism, and led to the development of different MR techniques to monitor metabolic changes in cancer tissues in vivo.

Magnetic resonance spectroscopy (MRS)

Magnetic resonance spectroscopy has been widely used to detect metabolic changes in cancerous as well as in normal tissues [26]. Different metabolic markers, detectable by MRS, not only provide information on biochemical changes in response to tumor growth but also delineate different metabolic tumor phenotypes. Proton MRS (1H MRS) is widely used MRS method to monitor metabolic changes in cancer tissue [27–32]. The other active nuclei such as, 31P (phosphorus), 13C (carbon) and 19F (fluorine) are also being used to monitor bioenergetics and metabolic flux in cancer [33–46].

1H MRS is most commonly used method to detect metabolic changes in cancer tissues [27–32]. The 1H signal from total choline (Cho) is significantly elevated in cancer tissue, which is shown to be correlated with cellular proliferation in cancer [47–50]. Choline ratios with other metabolites are routinely used to classify cancer aggressiveness. For example- Cho/(N-acetylaspartate (NAA)) ratio is used to distinguish low and high grade astrocytoma’s and gliomas [51], while Cho/(creatine) Cr is used to differentiate low grade glioma from benign lesion [52]. It has been shown that distinct patterns of Cho metabolism are associated with different gene expression profiles in the luminal and basal like breast cancers xenograft models [53], and the serial choline levels measured by MRS provide an early indicator of treatment response in the breast cancer [54]. Alteration in the profile of choline compounds is associated with the malignant transformation of breast, and ovarian cancers [55–57]. Both breast and ovarian cancer cells showed higher phosphocholine (PC) signal while glycerophosphocholine (GPC) signal was predominant in nonmalignant breast and ovarian epithelial cells [56, 58]. Not only 1H MRS but 31P MRS also has been used to detect the changes in choline metabolites such as phosphomonoesters, and phosphorylcholine in cancer, which has been proven valuable in monitoring response of tumors to anti-cancer therapy.

Magnetic resonance spectroscopic imaging (MRSI) provides spatial mapping of endogenous metabolites and thus can provide heterogeneous distribution of these metabolites in cancer tissue [59, 60]. The spatial mapping of Cho proton signal can reveal aggressive areas in tumor tissue and help to monitor therapeutic responses [61, 62]. In vivo MRSI improves diagnostic specificity of malignant human cancers and is becoming an important clinical tool for cancer’s management and care [63].

31P MRS, in spite of its lower sensitivity provides important information about cancer metabolism. 31P MRS detects metabolites such as phosphocreatine (PCr), nucleotide triphosphate (NTP), phosphomonoesters (PME), phosphorylcholine, PME and inorganic phosphate (Pi) [64]. Phosphomonoesters include phosphocholine, phosphoethanolamine and phosphoserine, while phosphorylcholine include glycerolphosphocholine, glycerophosphoethanolamine and glycerolphosphoserine. In breast cancer, 31P MRS showed increased concentration of PME compared to normal breast tissue [65] and following chemotherapy a decrease in the PME level was observed [66, 67]. Study on breast cancer cell lines showed higher phosphocholine in malignant cell line compared to nonmalignant cell line [58]. It has been shown that in some cancers malignant progression is associated with a switch from GPC to PC [57]. Elevated level of both PC and GPC has been detected in prostate cancer cells [68]. PME/PDE ratios predicted early response to chemotherapy in patients with soft tissue sarcomas [69]. In addition, 31P MRS studies have also showed that the ratio of PCr/Pi and NTP/Pi is correlated with the tumor oxygen level [70, 71].

Hyperpolarized MRI in cancer

Techniques using hyperpolarized 13C labeled pyruvate infusion to monitor increased glycolysis in cancer have the potential to improve the way MRI is used for detection and characterization of cancer. To date, 13C pyruvate has been the most widely used hyperpolarize substrate both in preclinical and clinical studies [72, 73]. Level of hyperpolarized [1-13C] lactate following intravenous injection of 13C pyruvate increases with cancer progression and reduces after therapy [74]. Flux of hyperpolarized 13C between pyruvate and lactate has been used to
visualize prostate cancer [75]. Hyperpolarized $^{13}$C lactate study in a transgenic prostate cancer mouse model showed that the hyperpolarized lactate level progressively increased with cancer aggressiveness and correlated significantly with histological grading [72]. Studies with lymphoma-bearing mice injected with hyperpolarized [1–$^{13}$C] pyruvate have shown lower rate of pyruvate to lactate conversion after onset of chemotherapy, which correlated with the amount of cell death caused by the chemotherapeutic drug [76].

Recently, hyperpolarized $^{13}$C glucose has been used to monitor the glycolytic flux in mouse lymphoma tumor model [77] (Fig. 1). Despite the short spin–lattice ($T_1$) relaxation of carbon in glucose $^{13}$C lactate signal was measured within tumor, which decreases following chemotherapeutic drug treatment. In addition, signal from 6-phosphogluconate was detected which is generated through the PPP. However, sensitivity of detection of hyperpolarized $^{13}$C lactate with hyperpolarized $^{13}$C glucose infusion was much lower than hyperpolarized $^{13}$C lactate detected following injection of hyperpolarized $^{13}$C pyruvate. Nonetheless, this method could provide a new way to monitor the glycolytic flux and PPP activity in tumor.

In a recent study, it has been shown that the tissue pH can be mapped through hyperpolarized MRI [78]. Since many pathological changes are associated with pH changes, monitoring the pH in vivo can provide useful information about the tissue pathological stage. The pH map can be generated noninvasively by targeting conversion of the injected hyperpolarized $^{13}$C labeled bicarbonate to hyperpolarized carbon dioxide in tumor tissues [78] (Fig. 2). The mapping of pH changes in tumor can be used as a marker for evaluating the treatment efficacy as well as in designing of the effective cancer treatment protocols.

In clinic, by using hyperpolarized technique the treatment response can be monitored within hours, and based on the observation more effective treatment could be initiated.

**Chemical exchange saturation transfer (CEST) imaging**

Chemical exchange saturation transfer (CEST) is a new contrast enhancement technique that enables the indirect detection of molecules and macromolecules possessing exchangeable protons [79–81]. In CEST experiment, these exchangeable protons can be specifically saturated using frequency selective radiofrequency (RF) saturation pulse which leads to the zero magnetization on these exchangeable protons, and their exchange with the bulk water protons decrease the bulk water signal [80, 81]. The decrease in bulk water signal can be quantified and mapped to provide high resolution images of specific molecules and macromolecules.

**Imaging of mobile protein and peptide in cancer**

Amide proton transfer (APT) imaging is one of the widely used CEST based methods which is being used to image mobile protein and peptides in cancers in vivo [82–86]. Briefly, APT imaging method depends on exchange between protons of free water and those of amide groups (–$\text{NH}$) of endogenous mobile proteins and peptides [87]. Higher numbers of such amide protons are reported in cancer compared to normal healthy tissue. APT imaging of the human brain tumor showed higher APT contrast in tumor region than contralateral normal brain parenchyma [83, 88–90]. It has been shown that APT can better discriminate tumor from edema and

![Fig. 1](image-url)
normal brain areas than conventional T2, T1 and FLAIR imaging [88]. APT imaging has been used to classify the tumors, which showed higher APT contrast in high grade tumor compared to low grade tumor [83] (Fig. 3). In a recent study, APT imaging has been used to distinguish tumor recurrence from radiation necrosis [89]. While the conventional methods cannot reliably differentiate between tumor recurrence and radiation necrosis, APT contrast was shown to be hyper-intense in tumor tissues and hypo-intense in necrotic areas (Fig. 4) [89]. APT was also used to evaluate the radiation treatment monitoring in cancer, which showed decreased APT contrast post radiation treatment [89].

Amide proton transfer weighted imaging has been also used to assess the early treatment response during short-term chemotherapy with temozolomide (TMZ) in mouse model of glioblastoma multiforme (GBM), which showed decreased APT contrast following treatment, while in control non-treated group increased APT contrast is observed [90] (Fig. 5). The treated group showed low level of Ki67, an index of tumor cells proliferation, than nontreated control tumor (Fig. 5). In another experiment, TMZ-resistant GBM line showed increase in both APT signal and levels of Ki67 despite the same course of TMZ treatment [90]. Based on these observations it has been suggested that the APT signal may be useful in monitoring the treatment response and to evaluate the tumor progression.

In a very recent study, APT was used to image orthotropic lung tumor in mouse model and has showed higher APT contrast in tumor [84] (Fig. 6). It is presumed that APT can be used as a potential biomarker to characterize and grade the lung cancer non-invasively in vivo. Applications of APT imaging are emerging in studies of other cancer types including breast cancer, prostate cancer, bladder cancer etc.
Treatment response to high intensity focused ultrasound (HIFU) in animal model of tumor has been monitored through APT weighted imaging [91]. A decrease in APT contrast in tumor following HIFU treatment was observed, which was complementary to the gadolinium (Gd) based study [91] (Fig. 7). This suggests that
APT can effectively replace the Gd based monitoring of HIFU treatment response in cancer. Moreover, APT uses endogenous mobile proteins and peptides for signal measurement while in Gd based study exogenous administration of contrast is required. Despite plethora of applications, the physiological basis of APT and APT changes are still not well understood.

CEST imaging of small metabolites in tumor
Role of different biochemical signatures in cancer malignancy is known since decades. Efforts have been made to quantify changes in these metabolites non-invasively using $^1$H MRS, which showed altered concentration of different metabolites in tumor tissue [26]. These metabolites include glutamate, creatine, myo-inositol, glycine, etc. However, $^1$H MRS suffers from poor resolution and does not provide information regarding heterogeneous distribution of metabolites concentration in cancer tissue. Recently, high resolution imaging of these metabolites has been performed using CEST imaging [92–94]. However, changes in pH and other biological factors may affect the quantification of CEST contrast from these metabolites in cancer. Most of these metabolites present intracellular in cancer, and it is well known that the intracellular pH in cancer mostly does not change, therefore, by using CEST method concentration changes of these metabolites in response to tumor aggressiveness can be quantified and may be used as a bio-marker to evaluate therapeutic responses.

Recently, glucose was used as exogenous CEST contrast agent to monitor the glucose CEST enhancement (GCE) in mouse model of colorectal cancers [95]. Higher GCE was observed in SW1222 than LS174T cancer (Fig. 8) [95]. Based on the findings, it was further suggested that the GCE can be used to distinguish tumor types with differing phenotypic characteristics. Since glucose is not toxic and is readily available it can be rapidly used in clinic to evaluate the different types of cancers.

Alterations in mucin expression and glycosylation are associated with the cancer progression and invasion [96]. Very recently CEST technique has been used to differentiate the glycosylated mucin tumor from under-glycosylated mucin tumor, and showed that the deglycosylation of mucin resulted in more than 75 % reduction in CEST contrast [97] (Fig. 9).

CEST imaging of protease enzyme expression
Developing proteolytic enzyme inhibitors is an active area of research and the ability to non-invasively
detect proteolytic enzyme activity would be valuable in selecting tumors for specific inhibitors and for detecting response to such agents. MRI Studies have been performed to detect the transglutaminase [98] and Hyaluronidase [99] activity in preclinical setup using contrast generated by a peptide linked to GdDTPA. Recently, Haris et al., have used GluCEST method to image the cathepsin protease activity in 9L tumor in rat model using poly-L-glutamate as a CEST imaging probe [100] (Fig. 10). Cathepsin protease expressions in tumor cleave the PLG into smaller fragments or its monomers and expose several glutamate amine protons, which can be monitored noninvasively using GluCEST technique. Since the elevated protease activity is highly associated with tumor malignancy [101], by monitoring the kinetics of poly-L-glutamate (PLG) cleavage tumor aggressiveness can be mapped. Further, PLG has been used as a macromolecule for the targeted cancer drugs delivery [102], this method can be potentially used to monitor targeted drug delivery as well as their efficacy on tumor cells. This technique may also provide a novel diagnostic tool for early detection of tumors and in effective anti-cancerous drug designing.

Fig. 7 Monitoring HIFU treatment in cancer. Proton anatomical image, APT weighted image and GD contrast enhanced image show the changes in tumor following HIFU treatment. Decreased APT contrast following HIFU was observed which is comparable to the Gd based contrast enhancement study. Reproduced with permission from John Wiley and Sons and Hectors et al. [91]
CEST imaging of cancer tissue redox potential

Tumor redox potential is an important marker to predict the biological as well as metabolic processes in tumor cells [103]. The tumor redox state has been recently imaged through CEST MRI in two different breast cancer mouse xenograft models, and correlated with the redox measurement by optical imaging method [104] (Fig. 11). Cai et al. have observed that the CEST contrast from tumor tissue linearly correlated with the Nicotinamide adenine dinucleotide (NADH) concentration as well as NADH redox state. Cai et al. [105] have further extended the CEST methods to characterize the prostate cancer in vivo in preclinical mouse model. Significantly higher CEST contrast was observed in PC-3 than DU-145 prostate cancer [105].

The above studies suggest that once validated, the CEST methods can be used in clinical setup to characterize tumor aggressiveness and to monitor the therapeutic responses in vivo.

MRI reporter genes in cancer

Gene expression in cancer cell can be monitored using reporter genes. Expression of reporter genes such as beta-galactosidase and luciferase has been examined...
ex vivo using immunohistochemical and histological techniques. Though, ex vivo methods provide high specificity and sensitivity, they cannot provide dynamic information, and require large number of animals to sacrifice for a longitudinal study. On the other hand, optical imaging can provide some structural and functional information about the gene expression in vivo but the sensitivity deteriorate very fast in the deeper part of tissue. These problems have been overcome by developing MR based reporter genes, which enable in vivo imaging of cell proliferation and migration.

Magnetic resonance reporter genes have potential to monitor the transgene expression in vivo noninvasively. These genes can be applied to interrogate the efficacy of gene therapy, to assess cellular differentiation, cell trafficking, and specific metabolic activity, and also assess changes in the microenvironment [106]. Various MR reporter genes probes are generated to monitor the
activity of different genes in biologic systems in vivo. Reporter genes basically generated by fusing promoter from a gene of interest to the gene of either a easily detectable protein or an enzyme capable of generating detectable contrast agent upon reaction with its substrate (Fig. 12). Gene expression imaging has had a revolutionary impact on laboratory study of cancer biology and is likely to play an important role in clinical trials in the future.

Ferritin MR reporter gene has been used to track the metastatic melanoma cells in lymph node [107] (Fig. 13) and to image the C6 glioma tumor cells [108] in vivo in preclinical mouse model. The cancer cells expressing the human ferritin protein can be detected as low signal intensity both on T2 and T1 relaxation weighted images. The change in the T2 and T1 relaxation properties can be used to track cancer cells in vivo as well as to evaluate the therapeutic effect of different drugs on cancer cells. In one of the study, ferritin high chain (FHC) overexpressing fibroblasts administered intraperitonealy in a mouse model of human ovarian cancer [109]. The recruitment of fibroblasts was monitored using R2 (1/T2) mapping of tumor which demonstrated high R2 value at the tumor rim compared to the tumor mouse which received control fibroblasts [109].

Arena et al. [110] have used the Lac Z as an MRI reporter gene to image proliferation of mouse melanoma cells. The lac Z expressing tumor cells can be easily distinguished by exogenous administration of a gadolinium based contrast agent. This gadolinium based contrast was designed as such that it maintain gadolinium ion in a water inaccessible position until it cleaved by the β-galactosidase enzyme express by the Lac Z. The cleavage results in transition of Gd ion in a water accessible position which generate strong positive contrast on T1 weighted MRI. Cancer cells expressing the Lac Z provides higher contrast than control after exogenous administration of contrast agent. In another study, the interaction between β-gal and a staining salt
i.e. 3,4-Cyclohexenoesculetin b-D-galactopyranoside in presence of ferric ions generated a strong hypointensity on T2* weighted image in tumor cells expressing LacZ [111] (Fig. 14).

With exception of ferritin all other MR reporter genes are rely on administration of substrate, which limits it’s access to all tissues. Poly-l-lysine ability to use as a CEST contrast provided the concept for the synthesis of an artificial gene rich in lysine residue [112]. The 9L rat glioma cells’ overexpressing this transgene is easily distinguished from the control 9L cells tumor (Fig. 15) [112].

Molecular MR imaging in cancer immunotherapy
Despite significant advances in chemotherapy and radiotherapy, cancer treatment remains an immense challenge. Cell-based cancer immunotherapy is gaining widespread attention as it provides a novel approach to treat cancer by triggering the patients’ own immune system to induce a potent anti-tumor response. Various cell types, such as lymphocytes (CD4+ and CD8+ T cells), dendritic cells (DCs) and natural killer cells (NK cells) have shown their therapeutic efficacy to treat cancer patients. This provides a highly selective way to kill cancerous cells with significantly less side effects on normal cells.

Currently, the only way to monitor the bio-distribution and pharmacokinetics of these therapeutic cells is rely on immunohistochemistry of the excised tissues. Non-invasive monitoring of the disposition, migration and destination of therapeutic cells will facilitate the development of cell based therapy. In general, response to immunotherapy is mostly evaluated by monitoring alteration in tumor size, tumor markers and improved survival rates, which require several weeks to months or even years for the treatment assessment. The localization of immune cells at the tumor site is an early marker for the treatment response, which is primarily examined through invasive histologic tissue analyses.

With the development in the molecular imaging technology it is possible to track the fate of these therapeutic cells in vivo non-invasively. Noninvasive molecular
imaging has potential to provide instant assessment of cell based therapy in both clinical and preclinical settings. These immunotherapeutic cells can be modified as such so that they can be easily detectable by MRI by introducing imaging probes into cells or attaching them on cell surface before injection. The obtained imaging signals can potentially be used as biomarkers for tumor response and for differentiating patients who are responders or nonresponders to immunotherapy.

In a recent study, DCs have been directly labeled using $^{19}$F, perfluoropolyether (PFPE) which can be visualized by MRI [113]. It is observed that PFPE have insignificant effect on DC function and moreover, by using $^{19}$F more selective images can be obtained as the background signal for $^{19}$F within tissues is negligible. With the advent of the iron oxide nanoparticles and their approval from FDA in clinical use open a new approach to detect the infiltrating immune cells to tumor cells in vivo. Cells labelled with nanoparticles produce strong hypointense contrast on MRI and showed promise of direct clinical translation. Sheu et al. [114] showed that tumor signal changes in $T_2^*$ relaxation time maps generated from gradient echo sequences after intra-arterial infusion of SPIO-labeled NK-92 cells.

To overcome the toxicity effect to normal cells, in a very recent approach cancer natural killer (NK) cells are genetically altered to recognize tumor associated surface antigens, which showed highly efficient toxicity against tumor cells with minimal or no effect on normal healthy cells. Different tumor associated antigens have been recognized as target for the NK cells- for example ErbB2/HER2 receptor tyrosine kinase in breast and ovarian cancer cells, pan-carcinoma antigen epithelial cell adhesion molecule (EpCAM) in prostate cancer cell, and CD20 differentiation antigen in B cell malignancies. EpCAM-targeted and ferumoxide labeled NK cells demonstrated substantial decreased $T_2^*$ signals in EpCAM-positive prostate cancers than ferumoxide labeled nontargeted parental NK-92 cells [115]. The relaxation maps $R_2^*$ ($R_2^* = 1/T_2^*$) can be generated and used to quantify labeled cells in tumor and other tissues. Figure 16 is showing a $T2^*$-weighted image and the corresponding $R2^*$ map of a Daudi Burkitt’s lymphoma in a mouse model before and 6 h post injection of ferumoxytol-labeled NK cells injection. Reproduced with permission from Thomas Hill Publisher and Sta Maria et al. [116].

**Conclusions**

Molecular MR imaging is well suited to measure molecular and cellular processes including metabolism, apoptosis, cell proliferation and biosynthetic pathways of different metabolites in vivo in cancer. Molecular imaging can play an important role in every aspect of oncology.
practice, including early disease detection, diagnosis, staging, personalized treatment, and treatment monitoring. Prostate, ovarian and lung cancer are just a few of the many types of cancer in which molecular imaging truly changed the direction and outcome of the patient care. The ability of molecular imaging to detect abnormalities very early in the progression of disease has the potential to change medicine from reactive to proactive, detecting and curing disease in its most treatable phase and saving countless lives. In medical setup, molecular MRI will pave the way toward a significant improvement in early detection of disease, therapy planning and monitoring the therapeutic outcomes.

Abbreviations
MR: magnetic resonance; SPECT: single photon emission computed tomography; PET: positron emission tomography; MRI: magnetic resonance imaging; PPP: pentose phosphate pathway; MRS: magnetic resonance spectroscopy; 31P: phosphorus; 13C: carbon; 19F: fluorine; 1H MRS: proton MR spectroscopy; Cho: choline; NAA: N-acetylaspartate; PC: phosphocholine; GPC: glycerol-PC; MRSI: magnetic resonance spectroscopic imaging; NTP: nucleotide triphosphate; PME: phosphomonoesters; PDE: phosphodiester; Pi: inorganic phosphate; CEST: chemical exchange saturation transfer; APT: amide proton transfer; T2: T2-weighted; Gd: gadolinium; HIFU: high intensity focused ultrasound; GCE: glucose CEST enhancement; Pi: inorganic phosphate; CEST: chemical exchange saturation transfer; APT: amide proton transfer; TMZ: temozolomide; GBM: glioblastoma multiforme; HiFU: high intensity focused ultrasound; GCE: glucose CEST enhancement; PLG: poly-L-glutamate; NADH: nicotinamide adenine dinucleotide; FHC: ferritin high chain; PFP: perfluoropolyether; SPIO: superparamagnetic iron oxide; NK: natural killer; EpCAM: epithelial cell adhesion molecule.

Authors’ contributions
MH conceived of and designed the study, collected literatures and wrote the manuscript. SKY, AR, AS, EW, HH, RR, and FMM discussed the previous findings and reviewed the manuscript. All the authors read and approved the final manuscript. SKY, AR, AS, EW, HH, RR, and FMM discussed the previous findings and reviewed the manuscript. All the authors read and approved the final manuscript.

Author details
1 Side Medical and Research Center, 26999, Doha, Qatar. 2 All India Institute of Medical Sciences, New Delhi, India. 3 Center for Biomedical Engineering, Indian Institute of Technology, Delhi, India. 4 Center for Magnetic Resonance and Optical Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Acknowledgements
Sidra Medical and Research Center has provided the resources station.

Compliance with ethical guidelines

Competing interests
The listed authors declare that they have no competing interests.

Received: 5 August 2015 Accepted: 3 September 2015
Published online: 23 September 2015

References
1. Weissleder R. Molecular imaging in cancer. Science. 2006;312:1168–71.
2. Schillaci O. Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. Semin Nucl Med. 2006;36:275–85.
3. Vandergrift C, Van de Wiele C, Mee G, Mertens K, Staelens S, Reuteling-sperger C, Fauvels P, Van Damme N, Peeters M. Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99 m tricaprylin-His-annexin V in a colorectal cancer xenograft model. Mol Imaging. 2012;11:135–47.
4. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683–93.
5. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–95.
6. Aliaga A, Rousseau JA, Cadorette J, Croteau E, van Liere JE, Lecomte R, Benard F. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol. 2007;9:144–50.
7. Hadjipanayis CG, Jiang H, Roberts DW, Yang L. Current and future clinical applications for optical imaging of cancer from intraoperative surgical guidance to cancer screening. Semin Oncol. 2011;38:109–18.
8. Kajzel EL, van der Pluijm G, Lowik CW. Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res. 2007;13:3490–7.
9. Peldichich K, Ittrich H. Magnetic resonance imaging of metastases in xenograft mouse models of cancer. Methods Mol Biol. 2014;1070:215–22.
10. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somfodi DM, Heijmink SW, Scheenen TW, Vos PC, Huismans H, van Oort IM, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66.
11. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001;220:31–30.
12. Padhani AR, Liu G, Koh DM, Chevenet TL, Thoery HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.
13. Yhee JT, Kim SA, Koo H, Son S, Ryu JH, Yoon IC, Choi K, Kwon IC, Kim K. Optical imaging of cancer-related proteases using near-infrared fluoroscopy matrice metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics. 2011;1:179–89.
14. Shah AT, Demory Beckler M, Walsh AJ, Jones WP, Pohlmann PR, Skala MC. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. Plos One. 2014;9:e90746.
15. Harada H, Kazioka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging. 2005;4:182–93.
16. Cairns RA, Harris IS, Mek TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.
17. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med. 2008;10:767–77.
18. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.
19. Warmoes MO, Locasale JW. Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochim Pharmacol. 2014;92:12–21.
20. Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell. 2014;5:592–602.
21. Chen QJ, Russo L. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 2012;1826:370–84.
22. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2:10.
23. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.
24. Garabedian RN. Cancer: an in vivo study with ex vivo corroboration. NMR Biomed. 2004;17:1–9.
25. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
26. Gillies R, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005;7:287–326.
27. Mahon MM, Williams AD, Scutter WP, Cox LJ, Mclndoe GA, Coutts GA, Dina R, deSouza NM. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed. 2004;17:1–9.
28. Kim JK, Kim DY, Lee YH, Sung NK, Chung DS, Kim OD, Kim KB. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external body surface coil. Magn Reson Imaging. 1998;16:1281–8.
29. Le HC, Lupu M, Kotedja K, Rosen N, Solit D, Koutcher JA. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med. 2009;62:1112–9.
30. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997;10:2–12.

31. Dowling C, Bollen AW, Nowosielski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol. 2001;22:604–12.

32. Majos C, Julia-Sape M, Alonso J, Serrallonga M, Aguilara C, Accebes JJ, Arus C, Gil J. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol. 2004;25:1696–704.

33. Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, Nelson MD Jr, Bluml S. Proton-decoupled 31P MRS in untreated pediatric brain tumors. Mag Reson Med. 2005;53:22–9.

34. Bluml S, Seymour KJ, Ross BD. Developmental changes in choline- and ethanolamine-containing compounds measured with proton-decoupled (31P) MRS in vivo in human brain. Mag Reson Med. 1999;42:643–54.

35. Glaholm J, Leach MO, Collins DJ, Mansi J, Sharp JC, Madden A, Smith IE, McCready VR. In vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet. 1989;1:1326–7.

36. Kristjansen PE, Spang-Thomsen M, Quistorff B. Different energy metabolism in two human small cell lung cancer subpopulations examined by 31P magnetic resonance spectroscopy and biochemical analysis in vivo and in vitro. Cancer Res. 1991;51:5160–4.

37. Kalra R, Wade KE, Hands L, Styles P, Camplonk P, Greenwall M, Adams GE, Harris AL, Radda GK. Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study. Br J Cancer. 1993;67:145–53.

38. Al-Saffar NM, Troy H, de Ramírez Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006;66:427–34.

39. Kurhanewicz J, Bok R, Nelson SJ, Vigneron DB. Current and potential applications of clinical 13C MR spectroscopy. J Nucl Med. 2008;49:341–4.

40. Rivenson-Segal D, Margalit R, Degani H. Glycocalyx as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13C) MRS. Am J Physiol Endocrinol Metab. 2002;283:E623–30.

41. Halliday KR, Fenoglio-Preiser C, Sillerud LO. Differentiation of human breast cancer using 31P magnetic resonance spectroscopy. Magn Reson Med. 1988;7:384–411.

42. Sillerud LO, Halliday KR, Griffey RH, Fenoglio-Preiser C, Sheppard S. In vivo 13C NMR spectroscopy of the human prostate. Magn Reson Med. 1999;42:643–5.

43. Findlay MP, Leach MO, Cunningham D, Collins DJ, Payne GS, Glaholm J, Mansi JL, McCready VR, Lacal JC, Judson IR, Chung YL. Noninvasive metabolic MR imaging, and characterization of tumor microenvironment. Dis Markers. 2013;2013:373942.

44. Bologa CT, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1H)MR spectroscopy—a pilot study at 4 T. Radiology. 2004;233:424–31.

45. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11:1835–48.

46. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D’Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2006;66:9369–76.

47. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999;59:80–4.

48. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007;120:1721–30.

49. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000;2:166–89.

50. Posse S, Otazo R, Dager SR, Alger J. MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging. 2013;37:1301–25.

51. Gruber S, Debiski BK, Pinker K, Chmelik M, Grabner G, Helbich T, Trattnig S, Bogner W. Three-dimensional proton MR spectroscopic imaging at 3T for the differentiation of benign and malignant breast lesions. Radiology. 2011;261:752–61.

52. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004;19:68–75.

53. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, Shungu DC, Shim H. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers. 2003;19:69–94.

54. Kemp GJ, Meyerspeier M, Moser E. Absolute quantification of phospho- and metabolite concentrations in human muscle in vivo by 31P MRS: a quantitative review. NMR Biomed. 2007;20:555–65.

55. Park JM, Park JH. Human in vivo 31P MR spectroscopy of benign and malignant breast tumors. Korean J Radiol. 2001;2:80–6.

56. Steen RG. Response of solid tumors to chemotherapy monitored by in vivo 31P magnetic nuclear resonance spectroscopy: a review. Cancer Res. 1989;49:4075–85.

57. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001;3:36–40.

58. Komoroski RA, Holder JC, Pappas AA, Finkbeiner AE. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magn Reson Med. 2001;46:911–3.

59. Koutcher JA, Ballon D, Graham M, Healey JH, Casper ES, Heelan R, Gerweck LE. 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy. Magn Reson Med. 1990;16:19–34.
70. Gerweck LE, Koutcher J, Zadi ST. Energy status parameters, hypoxia fraction and radioactivity across tumor types. Acta Oncol. 1995;34:335–8.
71. Nordsmark M, Grau C, Horsman MR, Jorgensen HS, Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol. 1995;34:329–34.
72. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang YY, Kohler SJ, Tropp J, Hurd RE, Yen YF, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15.
73. Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, Kurhanewicz J, Vigneron DB, Vandenberg SR, James CD, Nelson SJ. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol. 2010;12:133–44.
74. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Kogan F, Hariharan H, Reddy R. Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled bicarbonate. Nature. 2008;453:940–3.
75. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng. 2008;10:391–411.
76. Kogan F, Hariharan H, Reddy R. Chemical exchange saturation transfer (CEST) imaging: description of technique and potential clinical applications. Curr Radiol Rep. 2013;1:102–14.
77. Ward KM, Alextras AH, Babalan RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143:79–87.
78. Jia G, Abaza R, Williams JD, Zynger DL, Zhou J, Shah ZK, Patel M, Sammet S, Wei L, Bahmann RR, Knopp MW. Amide proton transfer transfer MRI of prostate cancer: a preliminary study. J Magn Reson Imaging. 2011;33:647–54.
79. Tokgo O, Kessinger CW, Huang G, Soesbe TC, Sagiyama K, Dimitrov I, Sherry AD, Gao J, Takahashi M. Characterization of lung cancer by amide proton transfer (APT) imaging: an in vivo study in an orthotopic mouse model. Plos One. 2013;8:e77019.
80. Yuan J, Chen S, King AD, Zhou J, Bhata KS, Zhang Q, Yeung DK, Wei J, Mok GS, Wang YY. Amide proton transfer-weighted imaging of the head and neck at 3T: a feasibility study on healthy volunteers and patients with head and neck cancer. NMR Biomed. 2014;27:1249–57.
81. Klop DW, Dula AN, Artinghaus LR, Ittman M, Daffner JR, Zabel B, Wang Y, Vemireddy V, et al. Amide proton transfer imaging in an experimental model of high intensity focused ultrasound-treated tumor tissue. Magn Reson Med. 2014;72:1113–22.
82. Cai K, Haris M, Singh A, Kogan F, Greenberg JH, Hariharan H, Dette JA, Reddy R. Magnetic resonance imaging of glutamate. Nat Med. 2012;18:302–6.
83. Haris M, Cai K, Singh A, Harisharan H, Reddy R. In vivo mapping of brain myo-inositol. Neuroimage. 2011;54:2079–85.
84. Haris M, Nanga RP, Singh A, Cai K, Kogan F, Harisharan H, Reddy R. Exchange rates of creatine kinase metabolites: feasibility of imaging creatine by chemical exchange saturation transfer MRI. NMR Biomed. 2012;25:1305–9.
85. Walker-Samuels S, Ramaswamy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, Richardson S, Gonzales M, Parkes HG, Arndt E, et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat Med. 2013;19:1067–72.
86. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.
87. Song X, Airan RD, Aniti DR, Bar-Shir A, Kadayakkara DK, Liu G, Gilad AA, van Zijl PC, McMahan MT, Bulte JW. Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cells. Nat Commun. 2015;6:6719.
88. Mazzoc M, Mehlman T, Tal TS, Greenberg CS, Dwershitz MW, Neeman M. Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. Cancer Res. 2005;65:1306–13.
89. Shiftan L, Israely T, Cohen M, Friedman V, Dafni H, Stern R, Neeman M. Magnetic resonance imaging visualization of hyalurondic acid in ovarian carcinoma. Cancer Res. 2005;65:10316–23.
90. Haris M, Singh A, Mohammed I, Ittynen R, Nanga RP, Debosse C, Kogan F, Kato K, Piantani H, et al. In vivo magnetic resonance imaging of tumor protease activity. Sci Rep. 2014;4:6081.
91. Jedeszko C, Sloane FB. Cysteine cathepsins in human cancer. Biol Chem. 2004;385:1017–27.
92. Li C. Poly-glutamic acid- and cancer drug conjugates. Adv Drug Deliv Rev. 2002;54:695–713.
93. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2013;2013:33–44.
94. Cai K, Xu HN, Singh A, Moon L, Haris M, Reddy R, Li LZ. Breast cancer redox heterogeneity detectable with chemical exchange saturation transfer (CEST) MRI. Mol Imaging Biol. 2014;16:670–9.
95. Cai K, Xu HN, Singh A, Haris M, Reddy R, Li LZ. Characterizing prostate tumor mouse xenografts with CEST and MT-MRI and redox scanning. Adv Exp Med Biol. 2013;765:39–45.
96. Ilgad AA, Ziv K, McMahon MT, van Zijl PC, Neeman M, Bulte JW. MRI reporter genes. J Nucl Med. 2008;49:1905–8.
97. Choi SH, Cho HR, Kim HS, Kim YH, Kang KW, Kim H, Moon WK. Imaging and quantification of metastatic melanoma cells in lymph nodes with a ferritin MR reporter in living mice. NMR Biomed. 2012;25:737–45.
98. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MR reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005;7:109–17.
99. Vanderslager MH, Rudol M, Addadi Y, Mofo S, Cohen B, Elam R, Neeman M. Ovarian carcinoma: quantitative biesponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors. Radiology. 2013;268:790–801.
100. Ares S, Singh JB, Gianello E, Stefania R, Aime S. Beta-Gal gene expression MR reporter in melanoma tumor cells. Design, synthesis, and in vitro and in vivo testing of a Gd(III) containing probe forming a high relaxivity, melanin-like structure upon beta-Gal enzymatic activation. Bioconjug Chem. 2011;22:2625–35.
101. Cui W, Liu L, Koldabgakar VO, Mason RP, S-Gal, a novel 11H MR reporter for beta-galactosidase. Magn Reson Med. 2010;64:645–71.
112. Gilad AA, McMahon MT, Walczak P, Winnard PT Jr, Raman V, van Laarhoven HW, Skoglund CM, Bulte JW, van Zijl PC. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007;25:217–9.

113. Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. NMR Biomed. 2013;26:860–71.

114. Sheu AY, Zhang Z, Omary RA, Larson AC. MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: preclinical studies in a rodent model. Invest Radiol. 2013;48:492–9.

115. Meier R, Golovko D, Tavri S, Henning TD, Knopp C, Piontek G, Rudelius M, Heinrich P, Wels WS, Daldrup-Link H. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magn Reson Med. 2011;65:756–63.

116. Sta Maria NS, Barnes SR, Jacobs RE. In vivo monitoring of natural killer cell trafficking during tumor immunotherapy. Magn Reson Insights. 2014;7:15–21.